Eli Lilly and Company (NYSE:LLY – Get Free Report)’s stock price fell 1.2% during mid-day trading on Thursday . The company traded as low as $1,171.71 and last traded at $1,175.0120. 2,624,870 shares changed hands during trading, a decline of 15% from the average session volume of 3,087,471 shares. The stock had previously closed at $1,189.41.
Eli Lilly and Company News Roundup
Here are the key news stories impacting Eli Lilly and Company this week:
- Positive Sentiment: A real-world study found that sustained use of Zepbound reduced hospital admissions, emergency-department visits and healthcare costs among adults over 55 with overweight or obesity. The findings could strengthen arguments for broader payer coverage, including Medicare’s GLP-1 Bridge program. Zepbound linked to lower healthcare costs in adults over age 55 with obesity
- Positive Sentiment: The FDA cleared an Alzheimer’s blood test developed by Lilly and Roche, potentially making Alzheimer’s screening more accessible and expanding Lilly’s diagnostics and treatment ecosystem. Eli Lilly Clears Big Hurdle in Alzheimer’s Fight
- Positive Sentiment: Lilly’s oncology revenue increased 11% in the first half of 2026, while newer products and pipeline candidates provide potential growth beyond the company’s GLP-1 franchise. Can Eli Lilly’s Oncology Portfolio Drive Growth Beyond GLP-1 Drugs?
- Positive Sentiment: Brenipatide has advanced into a Phase 3 depression study, adding another potential long-term pipeline opportunity, although clinical and regulatory risks remain. Lilly’s Brenipatide Steps Into Phase 3
Wall Street Analyst Weigh In
LLY has been the topic of several analyst reports. Berenberg Bank lifted their price target on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a report on Monday, June 22nd. Rothschild & Co Redburn increased their price objective on shares of Eli Lilly and Company from $880.00 to $900.00 in a research note on Thursday, May 7th. Royal Bank Of Canada raised their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an “outperform” rating in a research report on Wednesday, July 8th. Barclays lifted their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $1,419.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,292.18.
Eli Lilly and Company Trading Down 1.2%
The stock has a market cap of $1.11 trillion, a P/E ratio of 39.43, a price-to-earnings-growth ratio of 1.46 and a beta of 0.51. The stock’s 50-day moving average is $1,186.29 and its two-hundred day moving average is $1,063.74. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 EPS. Eli Lilly and Company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 36.35 EPS for the current year.
Eli Lilly and Company Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 23.22%.
Insider Activity at Eli Lilly and Company
In other news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the sale, the executive vice president directly owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. Insiders own 0.14% of the company’s stock.
Hedge Funds Weigh In On Eli Lilly and Company
Institutional investors have recently bought and sold shares of the business. California State Teachers Retirement System increased its stake in Eli Lilly and Company by 120,133.2% during the second quarter. California State Teachers Retirement System now owns 1,460,379,190 shares of the company’s stock worth $1,751,622,612,000 after acquiring an additional 1,459,164,568 shares during the last quarter. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $12,976,634,000. Bank of America Corp DE bought a new position in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $13,522,666,000. J. Stern & Co. LLP raised its holdings in Eli Lilly and Company by 46,191.3% during the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after buying an additional 4,038,502 shares during the period. Finally, Jupiter Topco LLC bought a new stake in Eli Lilly and Company in the second quarter worth $4,667,180,000. Institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Company Profile
Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.
Featured Stories
- Five stocks we like better than Eli Lilly and Company
- Nutanix’s Rally Has a Bigger Story Than Earnings as AMD’s AI Bet Takes Shape
- SEC Probe Puts Wall Street Leverage Risk Back in Focus
- A Bearish-Dollar Options Surge Raises the Stakes for Warsh at Jackson Hole
- Five Below’s Turnaround Is Working—But Has the Stock Run Too Far?
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
